Glioma is the most common type of brain cancer that originates from the glial cells. It constitutes about one-third of all brain cancers. Recently, transcriptomics, proteomics, and multiomics approaches have been harnessed to discover potential biomarkers and therapeutic targets in glioma. Moreover, post-translational modifications (PTMs) of proteins play a major role in cell biology and function and offer new avenues of research in cancer. Using unbiased multi-PTM bioinformatics analyses of two proteomic datasets of glioma available in the public domain, we identified 866 proteins with common PTMs from both studies. Out of these 866 proteins, 19 proteins were identified with the common PTMs, with the same site modifications pertaining to glioma. Importantly, the identified PTMs belonged to proteins involved in integrin PI3K/Akt/mTOR, JAK/STAT, and Ras/Raf/MAPK pathways. These pathways are essential for cell proliferation in tumor cells and thus involved in glioma progression. Taken together, these findings call for validation in larger datasets in glioma and brain cancers and with an eye to future drug discovery and diagnostic innovation. Bioinformatics-guided discovery of novel PTMs from the publicly available proteomic data can offer new avenues for innovation in cancer research.
Get full access to this article
View all access options for this article.
References
1.
AoudjitF, and VuoriK. (2012). Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract, 2012, 283181.
2.
BermanHM, WestbrookJ, FengZ, et al. (2000). The Protein Data Bank. Nucleic Acids Res, 28, 235–242.
3.
CalderwoodSK, and GongJ. (2016). Heat shock proteins promote cancer: it's a protection racket. Trends Biochem Sci, 41, 311–323.
4.
CalderwoodSK, MurshidA, and PrinceT. (2009). The shock of aging: molecular chaperones and the heat shock response in longevity and aging—a mini-review. Gerontology, 55, 550–558.
5.
ChesnelongC, ChaumeilMM, BloughMD, et al. (2014). Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro Oncol, 16, 686–695.
6.
DennisGJr., ShermanBT, HosackDA, et al. (2003). DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol, 4, P3.
7.
DeolankarSC, PatilAH, KoyanganaSG, et al. (2019). Dissecting Alzheimer's disease molecular substrates by proteomics and discovery of novel post-translational modifications. OMICS, 23, 350–361.
8.
DjuricU, LamKHB, KaoJ, et al. (2019). Defining protein pattern differences among molecular subtypes of diffuse gliomas using mass spectrometry. Mol Cell Proteomics, 18, 2029–2043.
9.
ErhartF, WeissT, KlingenbrunnerS, et al. (2019). Spheroid glioblastoma culture conditions as antigen source for dendritic cell-based immunotherapy: spheroid proteins are survival-relevant targets but can impair immunogenic interferon gamma production. Cytotherapy, 21, 643–658.
10.
GhezziD, SevrioukovaI, InvernizziF, et al. (2010). Severe X-linked mitochondrial encephalomyopathy associated with a mutation in apoptosis-inducing factor. Am J Hum Genet, 86, 639–649.
11.
GranerMW, and BignerDD. (2005). Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neuro Oncol, 7, 260–278.
12.
GuoX, SongJ, ZhaoJ, et al. (2019). Impact of ANXA5 polymorphisms on glioma risk and patient prognosis. J Neurooncol, 142, 11–26.
13.
HoffmanMD, SniatynskiMJ, and KastJ. (2008). Current approaches for global post-translational modification discovery and mass spectrometric analysis. Anal Chim Acta, 627, 50–61.
14.
KalininaJ, PengJ, RitchieJC, and Van MeirEG. (2011). Proteomics of gliomas: initial biomarker discovery and evolution of technology. Neuro Oncol, 13, 926–942.
15.
KallL, CanterburyJD, WestonJ, NobleWS, and MacCossMJ. (2007). Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat Methods, 4, 923–925.
16.
KaurB, KhwajaFW, SeversonEA, et al. (2005). Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol, 7, 134–153.
17.
KimJT, KimKD, SongEY, et al. (2006). Apoptosis-inducing factor (AIF) inhibits protein synthesis by interacting with the eukaryotic translation initiation factor 3 subunit p44 (eIF3g). FEBS Lett, 580, 6375–6383.
18.
LefrancF, Le RhunE, KissR, and WellerM. (2018). Glioblastoma quo vadis: will migration and invasiveness reemerge as therapeutic targets?. Cancer Treat Rev, 68, 145–154.
19.
LiaoJ, QianF, TchaboN, et al. (2014). Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One, 9, e84941.
20.
MesfinFB, and Al-DhahirMA. (2021). Gliomas. Treasure Island, FL:. StatPearls.
21.
MiH, and ThomasP. (2009). PANTHER pathway: an ontology-based pathway database coupled with data analysis tools. Methods Mol Biol, 563, 123–140.
22.
MiramarMD, CostantiniP, RavagnanL, et al. (2001). NADH oxidase activity of mitochondrial apoptosis-inducing factor. J Biol Chem, 276, 16391–16398.
23.
NakadaM, KitaD, WatanabeT, et al. (2011). Aberrant signaling pathways in glioma. Cancers (Basel), 3, 3242–3278.
24.
NevesMA, TotrovM, and AbagyanR. (2012). Docking and scoring with ICM: the benchmarking results and strategies for improvement. J Comput Aided Mol Des, 26, 675–686.
25.
O'SheaJP, ChouMF, QuaderSA, et al. (2013). pLogo: a probabilistic approach to visualizing sequence motifs. Nat Methods, 10, 1211–1212.
26.
PathanM, SamuelM, KeerthikumarS, and MathivananS. (2017). Unassigned MS/MS spectra: who am I?. Methods Mol Biol, 1549, 67–74.
27.
PatilAH, DattaKK, BeheraSK, et al. (2018). Dissecting candida pathobiology: post-translational modifications on the Candida tropicalis proteome. OMICS, 22, 544–552.
28.
Perez-RiverolY, CsordasA, BaiJ, et al. (2019). The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res, 47, D442–D450.
29.
PinkhamK, ParkDJ, HashemiaghdamA, et al. (2019). Stearoyl CoA desaturase is essential for regulation of endoplasmic reticulum homeostasis and tumor growth in glioblastoma cancer stem cells. Stem Cell Reports, 12, 712–727.
30.
PolisettyRV, GautamP, SharmaR, et al. (2012). LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signaling and other protein groups of regulatory functions. Mol Cell Proteomics, 11, M111.013565.
31.
RinaldiC, GrunseichC, SevrioukovaIF, et al. (2012). Cowchock syndrome is associated with a mutation in apoptosis-inducing factor. Am J Hum Genet, 91, 1095–1102.
32.
SevrioukovaIF. (2016). Structure/function relations in AIFM1 variants associated with neurodegenerative disorders. J Mol Biol, 428, 3650–3665.
33.
SinghV, RamM, KumarR, et al. (2017). Phosphorylation: implications in cancer. Protein J, 36, 1–6.
34.
SmithSJ, LongA, BarrowJH, et al. (2011). Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target. Neuro Oncol, 13, 1171–1177.
35.
SuMG, WengJT, HsuJB, et al. (2017). Investigation and identification of functional post-translational modification sites associated with drug binding and protein-protein interactions. BMC Syst Biol 11(Suppl 7),132.
36.
SusinSA, LorenzoHK, ZamzamiN, et al. (1999). Molecular characterization of mitochondrial apoptosis-inducing factor. Nature, 397, 441–446.
37.
SusinSA, ZamzamiN, CastedoM, et al. (1996). Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med, 184, 1331–1341.
38.
SzklarczykD, GableAL, LyonD, et al. (2019). STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res, 47, D607–D613.
39.
TagaT, and TabuK. (2020). Glioma progression and recurrence involving maintenance and expansion strategies of glioma stem cells by organizing self-advantageous niche microenvironments. Inflamm Regen, 40, 33.
40.
TausT, KocherT, PichlerP, et al. (2011). Universal and confident phosphorylation site localization using phosphoRS. J Proteome Res, 10, 5354–5362.
41.
ThomasTM, and YuJS. (2017). Metabolic regulation of glioma stem-like cells in the tumor micro-environment. Cancer Lett, 408, 174–181.
42.
WitalisonEE, ThompsonPR, and HofsethLJ. (2015). Protein arginine deiminases and associated citrullination: physiological functions and diseases associated with dysregulation. Curr Drug Targets, 16, 700–710.
43.
YangL, LinC, WangL, GuoH, and WangX. (2012). Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. Exp Cell Res, 318, 2417–2426.
44.
Yanovich-AradG, OfekP, YeiniE, et al. (2021). Proteogenomics of glioblastoma associates molecular patterns with survival. Cell Rep, 34, 108787.
45.
YuF, NgSS, ChowBK, et al. (2011). Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells. J Neurooncol, 103, 187–195.
46.
YuzhalinAE. (2019). Citrullination in cancer. Cancer Res, 79, 1274–1284.
47.
ZhangK, XuP, SowersJL, et al. (2017). Proteome analysis of hypoxic glioblastoma cells reveals sequential metabolic adaptation of one-carbon metabolic pathways. Mol Cell Proteomics, 16, 1906–1921.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
